Live Attenuated Influenza Vaccine As a Nasal Model for Influenza Infection

Description

The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)

Conditions

Influenza

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)

Live Attenuated Influenza Vaccine As a Nasal Model for Influenza Infection

Live Attenuated Influenza Vaccine As a Nasal Model for Influenza Infection

Condition
Influenza
Intervention / Treatment

-

Contacts and Locations

Birmingham

UAB Lung Health Center, Birmingham, Alabama, United States, 35233

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ages 18-49 years old,
  • * not yet received influenza vaccine for 2019-2020, and
  • * capable of giving signed informed consent.
  • * Immunocompromising condition (e.g. HIV/AIDS, chemotherapy, immune suppressing medications),
  • * active smoking within past 6 months,
  • * asthma, chronic lung/liver/kidney /neurologic/hematologic/metabolic disorders,cardiovascular disease (excluding isolated hypertension), diabetes mellitus, disease, congestive heart failure,
  • * pregnancy,
  • * current or recent (within the past month) upper/lower respiratory tract infection, chronic sinusitis/nasal allergies requiring frequent or daily therapy (including topical corticosteroids),
  • * prior adverse reaction to influenza vaccine,
  • * history of Guillain-Barre syndrome,
  • * egg allergy,
  • * close contact with an individual with severe immunodeficiency/immunosuppression.

Ages Eligible for Study

18 Years to 49 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Alabama at Birmingham,

Study Record Dates

2025-12-31